COVID-19 infection under omalizumab therapy for chronic spontaneous urticaria: three cases

Int J Dermatol. 2021 Feb;60(2):253-254. doi: 10.1111/ijd.15379. Epub 2020 Dec 17.

Authors

Erhan Ayhan¹, Murat Öztürk², İsa An³, Muhammed Bekçİbaşi⁴

Affiliations

¹ Department of Dermatology, University of Health Sciences Gazi Yaşargil Education and Research Hospital, Diyarbakır, Turkey.
² Department of Dermatology, Van Education and Research Hospital, Van, Turkey.
³ Department of Dermatology, Şanlıurfa Education and Research Hospital, Şanlıurfa, Turkey.
⁴ Department of Infectious Diseases and Clinical Microbiology, Bismil State Hospital, Diyarbakır, Turkey.

PMID: 33332576
DOI: 10.1111/ijd.15379

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Adult
Anti-Allergic Agents / therapeutic use*
COVID-19 / complications*
Chronic Urticaria / complications*
Chronic Urticaria / drug therapy*
Female
Humans
Male
Middle Aged
Omalizumab / therapeutic use*

Substances

Anti-Allergic Agents
Omalizumab